My main goal is to develop continuous production systems of cell culture-derived viral vaccines, with focus in Modified Vaccinia Ankara (MVA) virus and influenza virus. Continuous systems are known to be more efficient than batch, but previous studies have shown that virus replication in continuous mode is limited by the accumulation of defective interfering particles (DIPs). Also, continuous virus production has the risk of unwanted viral antigenic mutations that can arise after many days of virus replication. To solve these issues, I have been working in the production of a stable virus such as MVA in a two-stage continuous stirred tank bioreactor that can be used for recombinant vaccines production. We have also design and constructed a novel process for influenza whole-virus production that is based on a plug-flow tubular bioreactor system (patent submitted). Both systems, are good candidates to be used in continuous production of cell culture-derived vaccines.